Theresa Medina

7PUBLICATIONS
100CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Mechanobiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 02, 2026
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.

|Jun 01, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

|Jul 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes

|Jun 02, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Theresa Medina, Jason A Chesney, Harriet M Kluger

|Jan 09, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.

Sylvia M Lee, Omid Hamid, Robert Jotte

|May 25, 2023
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.

Jason J Luke, Sarina A Piha-Paul, Theresa Medina

Pageof 2

Frequent Collaborators

2 joint publications

Georgina V Long

2 joint publications

Omid Hamid

2 joint publications

Inderjit Mehmi

1 joint publications

Janice M Mehnert